Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.58 |
| ▸ | MPO | P05164 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30688366 | 1.00 | KMT2A (0.58) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL19897942 | 1.00 | KMT2A (0.58) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL18029006 | 0.87 | KMT2A (0.58) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL18029332 | 0.87 | KMT2A (0.58) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL24328916 | 0.86 | SMN1; SMN2 (0.57) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL2286478 | 0.84 | SCN9A (0.48) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL2286482 | 0.84 | SCN9A (0.48) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL24328254 | 0.82 | NR3C2 (0.47) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL18029267 | 0.81 | KMT2A (0.68) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL1460641 | 0.81 | KMT2A (0.68) | KMT2AKDM4EMAPTMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3759227-A1 | IMPROVED METHOD FOR THE SYNTHESIS OF TRYPTOPHAN ANALOGS IN AQUEOUS SOLVENTS AT REDUCED TEMPERATURES | California Institute of Technology (US) | 2021-01-06 | — | — | EP | claimed |
| US-10752927-B2 | Method for the synthesis of tryptophan analogs in aqueous solvents at reduced temperatures | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-08-25 | — | — | US | claimed |
| US-20190271016-A1 | METHOD FOR THE SYNTHESIS OF TRYPTOPHAN ANALOGS IN AQUEOUS SOLVENTS AT REDUCED TEMPERATURES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-09-05 | — | — | US | claimed |
| US-20260048134-A1 | PEPTIDE-BASED DELIVERY AGENT AND METHOD OF MAKING AND USING THE SAME | ENDOREL BIOSCIENCES LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250382646-A1 | ENGINEERED ENZYMES AND METHODS FOR THE SYNTHESIS OF DIVERSE TYROSINE ANALOGS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2025-12-18 | — | — | US | disclosed |
| US-12421534-B2 | Engineered enzymes and method for the synthesis of diverse tyrosine analogs | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250250569-A1 | PEPTIDE-BASED DELIVERY AGENT WITH ASPARAGINE-CONTAINING MASK PEPTIDE GROUP AND METHOD OF MAKING AND USING THE SAME | ENDOREL BIOSCIENCES LLC (US) | 2025-08-07 | — | — | US | disclosed |
| WO-2025128626-A1 | HYBRID PEPTIDE COMPOUNDS HAVING A MODIFIED LYSINE RESIDUE | CARMOT THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025128624-A2 | HYBRID PEPTIDE COMPOUNDS HAVING A SUBSTITUTED TRYPTOPHAN RESIDUE OR A TERMINAL SUBSTITUENT | CARMOT THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-4568707-A1 | PEPTIDE-BASED DELIVERY AGENT AND METHOD OF MAKING AND USING THE SAME | EndoRel Biosciences LLC (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-120076830-A | Peptide-based delivery agents and methods of making and using the same | 恩多雷尔生物科学有限责任公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20210315826-A1 | NATURAL FLUORESCENT POLYDEDRAL AMINO ACID CRYSTALS FOR EFFICIENT ENTRAPMENT AND SYSTEMIC DELIVERY OF HYDROPHOBIC SMALL MOLECULES | CORNELL UNIVERSITY | 2021-10-14 | — | — | US | disclosed |
| EP-3759227-A1 | IMPROVED METHOD FOR THE SYNTHESIS OF TRYPTOPHAN ANALOGS IN AQUEOUS SOLVENTS AT REDUCED TEMPERATURES | California Institute of Technology (US) | 2021-01-06 | — | — | EP | disclosed |
| WO-2020208191-A1 | NOVEL DHAP SYNTHASE | TECHNISCHE UNIVERSITÄT HAMBURG (DE) | 2020-10-15 | — | — | WO | disclosed |
| US-10752927-B2 | Method for the synthesis of tryptophan analogs in aqueous solvents at reduced temperatures | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-08-25 | — | — | US | disclosed |
| WO-2020023507-A1 | NATURAL FLUORESCENT POLYHEDRAL AMINO ACID CRYSTALS FOR EFFICIENT ENTRAPMENT AND SYSTEMIC DELIVERY OF HYDROPHOBIC SMALL MOLECULES | CORNELL UNIVERSITY (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20190271016-A1 | METHOD FOR THE SYNTHESIS OF TRYPTOPHAN ANALOGS IN AQUEOUS SOLVENTS AT REDUCED TEMPERATURES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-09-05 | — | — | US | disclosed |
| EP-3504332-A1 | ENGINEERED SYNTHASE FOR PRODUCTION OF TRYPTOPHAN DERIVATIVES AND INTRANSIGENT SUBSTRATES | California Institute of Technology (US) | 2019-07-03 | — | — | EP | disclosed |
| WO-2018039495-A1 | ENGINEERED SYNTHASE FOR PRODUCTION OF TRYPTOPHAN DERIVATIVES AND INTRANSIGENT SUBSTRATES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-03-01 | — | — | WO | disclosed |
| US-20180057806-A1 | ENGINEERED SYNTHASE FOR PRODUCTION OF TRYPTOPHAN DERIVATIVES AND INTRANSIGENT SUBSTRATES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048134-A1 | PEPTIDE-BASED DELIVERY AGENT AND METHOD OF MAKING AND USING THE SAME | FABP1, LAMP1, SLC7A1 | KMT2A 2388/4885KDM4E 3700/4885MAPT 3343/4885 |
| US-20250250569-A1 | PEPTIDE-BASED DELIVERY AGENT WITH ASPARAGINE-CONTAINING MASK PEPTIDE GROUP AND METHOD OF MAKING AND USING THE SAME | LNPEP, ASNS, DNPEP | KMT2A 4087/4885KDM4E 4641/4885MAPT 849/4885 |
| US-20180057806-A1 | ENGINEERED SYNTHASE FOR PRODUCTION OF TRYPTOPHAN DERIVATIVES AND INTRANSIGENT SUBSTRATES | WARS1, TPH1, TPH2 | KMT2A 1560/4885KDM4E 2269/4885MAPT 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.